Vanguard Group Inc. Sells 352,265 Shares of Ralliant Corporation $RAL

Key Points

• Vanguard trimmed its stake in Ralliant by 2.4%, selling 352,265 shares and leaving it with 14,237,158 shares (about 12.62% of the company, valued at $724.8M); several other institutions also made large moves, including new stakes from Viking Global and State Street and big increases from Invesco and UBS.
• Analysts have cut some price targets (Barclays, Truist, Citi) but sentiment remains generally positive with seven Buys, four Holds and one Sell; Ralliant's consensus rating is a "Moderate Buy" with an average target of $50.50.
• Insiders bought stock (a director and the SVP increased their holdings), and the company beat Q4 estimates on EPS ($0.69 vs. $0.67) and revenue, while guiding Q1 2026 EPS to 0.460–0.520 and FY2026 EPS to 2.220–2.420.

Vanguard Group Inc. lessened its stake in Ralliant Corporation (NYSE:RAL - Free Report) by 2.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,237,158 shares of the company's stock after selling 352,265 shares during the period. Vanguard Group Inc. owned about 12.62% of Ralliant worth $724,814,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in RAL. Viking Global Investors LP bought a new stake in shares of Ralliant in the 2nd quarter valued at about $257,200,000. State Street Corp bought a new stake in shares of Ralliant in the 2nd quarter valued at about $213,096,000. Invesco Ltd. grew its position in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company's stock valued at $169,309,000 after buying an additional 1,835,128 shares during the last quarter. UBS Group AG grew its position in shares of Ralliant by 660.3% in the 3rd quarter. UBS Group AG now owns 1,865,072 shares of the company's stock valued at $81,560,000 after buying an additional 1,619,770 shares during the last quarter. Finally, Capital World Investors bought a new stake in shares of Ralliant in the 3rd quarter valued at about $67,885,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays reduced their price target on Ralliant from $60.00 to $52.00 and set an "overweight" rating on the stock in a research report on Monday, February 9th. Truist Financial reduced their price target on Ralliant from $62.00 to $49.00 and set a "buy" rating on the stock in a research report on Friday, February 6th. Citigroup reduced their price target on Ralliant from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, February 6th. Morgan Stanley reissued an "overweight" rating and issued a $45.00 price objective on shares of Ralliant in a research note on Friday, February 6th. Finally, Vertical Research raised Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price objective on the stock in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ralliant presently has an average rating of "Moderate Buy" and an average target price of $50.50.

Insider Activity

In other news, Director Kevin E. Bryant acquired 1,250 shares of the firm's stock in a transaction dated Friday, February 6th. The stock was purchased at an average price of $39.97 per share, for a total transaction of $49,962.50. Following the completion of the acquisition, the director directly owned 4,653 shares in the company, valued at $185,980.41. The trade was a 36.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Amir A. Kazmi acquired 2,545 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $39.27 per share, with a total value of $99,942.15. Following the acquisition, the senior vice president owned 39,699 shares of the company's stock, valued at approximately $1,558,979.73. This represents a 6.85% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 8,145 shares of company stock valued at $332,233.

Ralliant Trading Down 0.4%

NYSE RAL opened at $45.52 on Monday. The company has a market cap of $5.10 billion and a price-to-earnings ratio of 23.23. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $57.02. The business has a 50 day moving average price of $44.09 and a 200-day moving average price of $46.92. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS. As a group, equities analysts expect that Ralliant Corporation will post 2.37 earnings per share for the current fiscal year.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.